Drugs · acquisition-cost intelligence
Budesonide Inhalation Suspension
Budesonide· ingredient budesonideCorticosteroids· BUDESONIDE 1 mg/2mL; BUDESONIDE .25 mg/2mL; BUDESONIDE .5 mg/2mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$0.76862
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per ML — the trend nobody else shows. 7 weeks.
2025-06-182026-05-20
Same-ingredient options by acquisition cost
Other budesonide products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.
| Product | NADAC / ML | vs this |
|---|---|---|
| budesonide | $0.52084 | −$0.24780 |
| Budesonide Inhalation Suspension | $0.69110 | −$0.07750 |
| Budesonide Inhalation | $0.72986 | −$0.03880 |
| Budesonide | $1.39 | +$0.62220 |
| budesonide | $9.31 | +$8.54 |
| Uceris | $11.99 | +$11.22 |
| BREYNA | $19.78 | +$19.01 |
Medicare Part D coverage · CY2026
On 257 plan formularies · typical tier 4
Prior auth 100% · Step therapy 0% · Quantity limit 63% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.